Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Emgality, emgality prefilled syringe, emgality prefilled pen
Synonyms :
galcanezumab
Class :
Calcitonin gene-related peptide inhibitors
Brand Name :
Emgality, emgality prefilled syringe, emgality prefilled pen
Synonyms :
galcanezumab
Class :
Calcitonin gene-related peptide inhibitors
Dosage Forms & Strengths
Injectable solutions
Single-dose prefilled syringe
100mg/mL
120mg/mL
Single-dose prefilled pen
120mg/mL
Indicated for the preventive migraine treatment:
Initial dose: 240mg subcutaneous once a month
Maintenance dose: 120mg subcutaneously monthly once
Indicated for episodic cluster headache:
Initial dose: 300mg subcutaneous at the onset of cluster headache
Maintenance dose: 300mg subcutaneously monthly once until the end of cluster headaches
Dose Adjustments
Hepatic impairment
No dedicated studies have been conducted to specifically evaluate the effects of hepatic impairment on the pharmacokinetics of galcanezumab
Renal impairment
No dedicated studies have been conducted to specifically evaluate the effects of hepatic impairment on the pharmacokinetics of galcanezumab
Safety and efficacy not establishedÂ
Refer adult dosingÂ
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
measles, mumps, rubella, and varicella vaccine, live (Rx)
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
measles mumps and rubella vaccine, live
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
smallpox (vaccinia) vaccine, live
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
respiratory syncytial virus vaccine, adjuvanted
may decrease the therapeutic effect when combined with Vaccines
respiratory syncytial virus (RSV) vaccine
may decrease the therapeutic effect when combined with Vaccines
poliovirus vaccine, live, trivalent
may decrease the therapeutic effect when combined with Vaccines
poliovirus vaccine inactivated
may decrease the therapeutic effect when combined with Vaccines
respiratory syncytial virus vaccine, adjuvanted
may decrease the therapeutic effect when combined with Vaccines
respiratory syncytial virus (RSV) vaccine
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may decrease the therapeutic activity of Fc receptor-binding agents
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk of adverse effects when combined
measles, mumps, rubella, and varicella vaccine, live (Rx)
immune globulins decrease the efficacy of live vaccines
measles mumps and rubella vaccine, live
immune globulins decrease the efficacy of live vaccines
immune globulins decrease the efficacy of live vaccines
smallpox (vaccinia) vaccine, live
immune globulins decrease the efficacy of live vaccines
immune globulins decrease the efficacy of live vaccines
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
bazedoxifene/conjugated estrogens
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
may have an increased thrombogenic effect when combined with anthrax immune globulin
may have an increased thrombogenic effect when combined with anthrax immune globulin
It exerts its action by binding to CGRP (calcitonin gene-related peptide), a protein, which transmits pain signals in the body. By binding to CGRP, galcanezumab blocks its activity and reduces the levels of pain experienced by the patient.
Frequency defined
>10%
Reactions at the site of injection
Frequency not defined
Anaphylaxis
Angioedema
Skin rashes
Black box warning
No specific black box warning is available
Hypersensitivity
Pregnancy & breastfeeding:
Pregnancy consideration:
Safety and efficacy study about the use of galcanezumab in pregnancy is not established
Breastfeeding warnings:
Data about the excretion of drug into breast milk is not known.
Pregnancy category:
Pharmacology:
Galcanezumab is a monoclonal antibody and an antagonist of CGRP (calcitonin-gene related peptide). This is indicated in treating migraine and administered as a subcutaneous injection, usually once a month.
Pharmacodynamics:
During clinical trials, it was found to reduce the number of migraine headache days significantly and was well tolerated. Analysis of results after an experiment (post-hoc) explained that 32% of the patients responded to galcanezumab when compared to placebo for which the response rate was 18%.
Pharmacokinetics:
Absorption:Â It reaches the maximum concentration in 5 days following single-dose administration.
Distribution: The volume of distribution is 7.3L. The interindividual variability may be noticed by 34%.
Metabolism: The drug is known to be degraded into amino acids and small peptides by proteolysis.
Elimination: It is eliminated through intracellular catabolism, and after that receptor-mediated or fluid-phase endocytosis
Half-life: 25 to 30 days
Administration
It is administered subcutaneously only. It must be administered in the thigh, abdomen, back of the buttocks, or upper arm.
Never inject into areas where the skin is hard, bruised, red, or tender.
Patient information leaflet
Generic Name:Â galcanezumab
Why do we use galcanezumab?
Galcanezumab is an antagonist of CGRP. It is used to treat cluster headaches and prevent migraines. It was first developed by Eli Lilly and company. Humanized monoclonal antibodies have decreased the frequency of migraine headaches as suggested by early clinical trials.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
